Bulls vs Bears
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
AtriCure Inc has a consensus price target of $51.67 based on the ratings of 12 analysts. The high is $75 issued by SVB Leerink on May 4, 2022. The low is $40 issued by JP Morgan on October 30, 2024. The 3 most-recent analyst ratings were released by Citizens Capital Markets, Canaccord Genuity, and JP Morgan on April 2, 2025, March 28, 2025, and March 27, 2025, respectively. With an average price target of $52.67 between Citizens Capital Markets, Canaccord Genuity, and JP Morgan, there's an implied 68.21% upside for AtriCure Inc from these most-recent analyst ratings.
1calculated from analyst ratings
Buy Now | Get Alert | |||||||
---|---|---|---|---|---|---|---|---|
04/02/2025 | Buy Now | 91.63% | Citizens Capital Markets | Daniel Stauder36% | $60 → $60 | Reiterates | Market Outperform → Market Outperform | Get Alert |
03/28/2025 | Buy Now | 66.08% | Canaccord Genuity | William Plovanic57% | $66 → $52 | Maintains | Buy | Get Alert |
03/27/2025 | Buy Now | 46.92% | JP Morgan | Lilia-Celine Lozada29% | $51 → $46 | Maintains | Overweight | Get Alert |
03/27/2025 | Buy Now | 62.89% | Needham | Mike Matson57% | $51 → $51 | Reiterates | Buy → Buy | Get Alert |
03/21/2025 | Buy Now | 62.89% | Needham | Mike Matson57% | $51 → $51 | Reiterates | Buy → Buy | Get Alert |
02/13/2025 | Buy Now | 43.72% | Oppenheimer | Suraj Kalia53% | $36 → $45 | Maintains | Outperform | Get Alert |
02/13/2025 | Buy Now | 59.69% | Piper Sandler | Matt O'Brien51% | $40 → $50 | Maintains | Overweight | Get Alert |
02/13/2025 | Buy Now | 91.63% | JMP Securities | Daniel Stauder36% | $60 → $60 | Reiterates | Market Outperform → Market Outperform | Get Alert |
02/13/2025 | Buy Now | 53.31% | Stifel | Rick Wise74% | $36 → $48 | Maintains | Buy | Get Alert |
02/13/2025 | Buy Now | 62.89% | Needham | Mike Matson57% | $51 → $51 | Reiterates | Buy → Buy | Get Alert |
02/13/2025 | Buy Now | 110.8% | Canaccord Genuity | William Plovanic57% | $61 → $66 | Maintains | Buy | Get Alert |
02/11/2025 | Buy Now | 62.89% | JP Morgan | Lilia-Celine Lozada29% | $40 → $51 | Maintains | Overweight | Get Alert |
02/10/2025 | Buy Now | 91.63% | JMP Securities | Daniel Stauder36% | $60 → $60 | Reiterates | Market Outperform → Market Outperform | Get Alert |
01/22/2025 | Buy Now | 62.89% | Needham | Mike Matson57% | $40 → $51 | Maintains | Buy | Get Alert |
01/13/2025 | Buy Now | 27.75% | Needham | Mike Matson57% | $40 → $40 | Reiterates | Buy → Buy | Get Alert |
12/17/2024 | Buy Now | 27.75% | JP Morgan | Lilia-Celine Lozada29% | → $40 | Assumes | → Overweight | Get Alert |
12/09/2024 | Buy Now | 94.83% | Canaccord Genuity | William Plovanic57% | $53 → $61 | Maintains | Buy | Get Alert |
10/30/2024 | Buy Now | 69.27% | Canaccord Genuity | William Plovanic57% | $49 → $53 | Maintains | Buy | Get Alert |
10/30/2024 | Buy Now | 14.98% | Oppenheimer | Suraj Kalia53% | $32 → $36 | Maintains | Outperform | Get Alert |
10/30/2024 | Buy Now | 27.75% | JP Morgan | Robbie Marcus67% | $30 → $40 | Maintains | Overweight | Get Alert |
10/30/2024 | Buy Now | 27.75% | UBS | Danielle Antalffy57% | $35 → $40 | Maintains | Buy | Get Alert |
10/30/2024 | Buy Now | 27.75% | Needham | Mike Matson57% | $34 → $40 | Maintains | Buy | Get Alert |
07/31/2024 | Buy Now | 69.27% | BTIG | Marie Thibault63% | $58 → $53 | Maintains | Buy | Get Alert |
07/31/2024 | Buy Now | -4.18% | JP Morgan | Robbie Marcus67% | $34 → $30 | Maintains | Overweight | Get Alert |
07/31/2024 | Buy Now | -16.96% | Stifel | Rick Wise74% | $30 → $26 | Maintains | Buy | Get Alert |
07/31/2024 | Buy Now | 27.75% | Piper Sandler | Matt O'Brien51% | $65 → $40 | Maintains | Overweight | Get Alert |
07/31/2024 | Buy Now | 8.59% | Needham | Mike Matson57% | $40 → $34 | Maintains | Buy | Get Alert |
07/08/2024 | Buy Now | 27.75% | Needham | Mike Matson57% | $40 → $40 | Reiterates | Buy → Buy | Get Alert |
05/02/2024 | Buy Now | 56.5% | Canaccord Genuity | William Plovanic57% | $57 → $49 | Maintains | Buy | Get Alert |
05/02/2024 | Buy Now | 8.59% | JP Morgan | Robbie Marcus67% | $42 → $34 | Maintains | Overweight | Get Alert |
05/02/2024 | Buy Now | 27.75% | Needham | Mike Matson57% | $46 → $40 | Maintains | Buy | Get Alert |
04/23/2024 | Buy Now | 2.2% | Oppenheimer | Suraj Kalia53% | → $32 | Upgrade | Perform → Outperform | Get Alert |
04/10/2024 | Buy Now | 46.92% | Needham | Mike Matson57% | $46 → $46 | Reiterates | Buy → Buy | Get Alert |
02/16/2024 | Buy Now | 85.24% | UBS | Danielle Antalffy57% | $57 → $58 | Maintains | Buy | Get Alert |
02/16/2024 | Buy Now | 34.14% | Stifel | Rick Wise74% | $50 → $42 | Maintains | Buy | Get Alert |
02/16/2024 | Buy Now | 46.92% | Needham | Mike Matson57% | $44 → $46 | Maintains | Buy | Get Alert |
01/22/2024 | Buy Now | 82.05% | UBS | Danielle Antalffy57% | $56 → $57 | Maintains | Buy | Get Alert |
01/04/2024 | Buy Now | 40.53% | Needham | Mike Matson57% | $49 → $44 | Maintains | Buy | Get Alert |
11/29/2023 | Buy Now | 91.63% | JMP Securities | Daniel Stauder36% | → $60 | Reiterates | Market Outperform → Market Outperform | Get Alert |
11/29/2023 | Buy Now | 56.5% | Needham | Mike Matson57% | → $49 | Reiterates | Buy → Buy | Get Alert |
11/02/2023 | Buy Now | 59.69% | JP Morgan | Robbie Marcus67% | $60 → $50 | Maintains | Overweight | Get Alert |
11/02/2023 | Buy Now | 56.5% | Needham | Mike Matson57% | $68 → $49 | Maintains | Buy | Get Alert |
10/23/2023 | Buy Now | 91.63% | JMP Securities | Daniel Stauder36% | → $60 | Initiates | → Market Outperform | Get Alert |
09/29/2023 | Buy Now | 78.86% | UBS | Danielle Antalffy57% | → $56 | Initiates | → Buy | Get Alert |
07/26/2023 | Buy Now | 117.18% | Needham | Mike Matson57% | $60 → $68 | Maintains | Buy | Get Alert |
06/02/2023 | Buy Now | 91.63% | Needham | Mike Matson57% | → $60 | Reiterates | Buy → Buy | Get Alert |
05/03/2023 | Buy Now | 91.63% | Needham | Mike Matson57% | $58 → $60 | Maintains | Buy | Get Alert |
04/17/2023 | Buy Now | 85.24% | Needham | Mike Matson57% | → $58 | Maintains | Buy | Get Alert |
02/22/2023 | Buy Now | 75.66% | BTIG | Marie Thibault63% | $65 → $55 | Maintains | Buy | Get Alert |
02/22/2023 | Buy Now | 53.31% | Stifel | Rick Wise74% | $55 → $48 | Maintains | Buy | Get Alert |
02/22/2023 | Buy Now | 136.35% | Canaccord Genuity | William Plovanic57% | $81 → $74 | Maintains | Buy | Get Alert |
02/22/2023 | Buy Now | 85.24% | Needham | Mike Matson57% | → $58 | Reiterates | → Buy | Get Alert |
02/06/2023 | Buy Now | 158.7% | Canaccord Genuity | William Plovanic57% | $67 → $81 | Maintains | Buy | Get Alert |
12/19/2022 | Buy Now | 85.24% | Needham | Mike Matson57% | $55 → $58 | Maintains | Buy | Get Alert |
11/02/2022 | Buy Now | 107.6% | Canaccord Genuity | William Plovanic57% | $72 → $65 | Maintains | Buy | Get Alert |
11/02/2022 | Buy Now | 75.66% | Needham | Mike Matson57% | $65 → $55 | Maintains | Buy | Get Alert |
10/17/2022 | Buy Now | 126.76% | BTIG | Marie Thibault63% | $75 → $71 | Maintains | Buy | Get Alert |
08/03/2022 | Buy Now | 75.66% | Piper Sandler | Matt O'Brien51% | $90 → $55 | Maintains | Overweight | Get Alert |
08/03/2022 | Buy Now | 107.6% | Needham | Mike Matson57% | $55 → $65 | Maintains | Buy | Get Alert |
07/18/2022 | Buy Now | 59.69% | Stifel | Rick Wise74% | $70 → $50 | Maintains | Buy | Get Alert |
06/28/2022 | Buy Now | 75.66% | Needham | Mike Matson57% | $67 → $55 | Maintains | Buy | Get Alert |
06/24/2022 | Buy Now | 139.54% | BTIG | Marie Thibault63% | $94 → $75 | Maintains | Buy | Get Alert |
05/04/2022 | Buy Now | 113.99% | Needham | Mike Matson57% | $79 → $67 | Maintains | Buy | Get Alert |
05/04/2022 | Buy Now | 139.54% | SVB Leerink | Danielle Antalffy57% | $95 → $75 | Maintains | Outperform | Get Alert |
The latest price target for AtriCure (NASDAQ:ATRC) was reported by Citizens Capital Markets on April 2, 2025. The analyst firm set a price target for $60.00 expecting ATRC to rise to within 12 months (a possible 91.63% upside). 33 analyst firms have reported ratings in the last year.
The latest analyst rating for AtriCure (NASDAQ:ATRC) was provided by Citizens Capital Markets, and AtriCure reiterated their market outperform rating.
The last upgrade for AtriCure Inc happened on April 23, 2024 when Oppenheimer raised their price target to $32. Oppenheimer previously had a perform for AtriCure Inc.
There is no last downgrade for AtriCure.
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of AtriCure, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for AtriCure was filed on April 2, 2025 so you should expect the next rating to be made available sometime around April 2, 2026.
While ratings are subjective and will change, the latest AtriCure (ATRC) rating was a reiterated with a price target of $60.00 to $60.00. The current price AtriCure (ATRC) is trading at is $31.31, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.